Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Swissmedic-regulated GLP Bioanalysis for Pharmacokinetic Studies of Novel Antibody-Drug Conjugates

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Swissmedic-regulated GLP Bioanalysis for Pharmacokinetic Studies of Novel Antibody-Drug Conjugates

Swissmedic-Regulated GxP Bioanalysis for Pharmacokinetic Studies

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    How do you manage the bioanalysis of the three distinct analytes (total antibody, conjugated antibody, and unconjugated payload) under Swissmedic GxP?

    Our strategy involves developing and validating a suite of parallel ligand-binding assays (LBAs) and, when required, LC-MS/MS methods. For total antibody, we typically use a generic anti-human IgG capture/detection format. For the conjugated antibody, we employ an assay format that specifically targets both the antibody and the payload-linker. The unconjugated payload is quantified using highly sensitive LC-MS/MS methods. All assays are validated according to current Swissmedic and international guidelines within our GxP-compliant framework to ensure data integrity for regulatory submission.

    What are the specific validation requirements for ligand-binding assays for novel antibody-payload conjugates submitted to Swissmedic?

    Swissmedic aligns closely with EMA and FDA guidelines for LBA validation. This requires a comprehensive assessment of specificity, selectivity, sensitivity (LLOQ), accuracy, precision, and stability. For novel antibody-payload conjugates, we place particular emphasis on characterizing potential matrix effects and assessing the impact of anti-drug antibodies (ADAs) on pharmacokinetic assay performance. All validation parameters and acceptance criteria are pre-defined in a detailed validation plan for full transparency and regulatory compliance.

    How does Franklin Biolabs ensure data integrity and traceability for studies intended for Swissmedic submission?

    Our quality system is built for rigorous regulatory scrutiny. All GxP studies are conducted within a 21 CFR Part 11 compliant environment, utilizing validated LIMS and electronic lab notebook (ELN) systems. We maintain a complete audit trail from sample receipt to final report generation. This ensures every data point is traceable, verifiable, and defensible during regulatory review by Swissmedic. Our >100,000 sq ft facility is designed for secure sample management and data handling.

Executive Summary

Characterizing the pharmacokinetic profile of a novel antibody-payload conjugate requires a multi-analyte bioanalytical strategy that can withstand Swissmedic regulatory review. The approach must simultaneously quantify total antibody, conjugated antibody, and the released cytotoxic payload. Franklin Biolabs provides validated, GxP-compliant ligand-binding and LC-MS/MS assays specifically designed to deconstruct the complex in vivo behavior of these tripartite molecules, generating the precise data required for IND-enabling studies and successful regulatory filings.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

The Analytical Complexity of Antibody-Payload Conjugates

The pharmacokinetic profile of an antibody-payload conjugate is a composite of at least three distinct molecular species. Each component possesses unique distribution and clearance characteristics that must be individually quantified to build a complete model of the therapeutic’s behavior.

  • Total Antibody: Measures all antibody-containing species, regardless of conjugation status. This is foundational for understanding overall antibody clearance.

  • Conjugated Antibody: Quantifies the therapeutically active species carrying the payload. This is a direct measure of the delivery vehicle’s concentration over time.

  • Unconjugated Payload: Measures the cytotoxic agent after its release from the antibody. This is vital for assessing efficacy and understanding potential toxicities related to non-target tissue biodistribution.

Navigating Swissmedic GxP Requirements

For programs targeting Swiss regulatory approval, all bioanalytical methods must be developed and validated under a stringent GxP quality system. Franklin Biolabs provides this framework, ensuring that every aspect of the study : from method development to sample analysis and reporting : is conducted in compliance with Swissmedic expectations. Our experience contributes to a consistent 18-24 month IND timeline for our partners. Since the Franklin Biolabs brand launch in 2024, programs relying on our GxP data packages have maintained a 100% IND success rate, a record established by our core scientific team since 2019.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Strategic Insights for Bioanalytical Design

The principles of characterizing complex biologics can be informed by work in other advanced modalities. For instance, studies in gene therapy vector development highlight the importance of understanding tissue-specific expression and biodistribution. The selection of reporter proteins to track vector activity (PMID: 17510373) is conceptually similar to the challenge of quantifying payload release in specific tissues. Both require assays sensitive enough to measure low-level events in complex biological matrices.

Engineering vectors to modulate their biodistribution (PMID: 39001819) underscores how molecular design directly impacts in vivo fate. An antibody-payload conjugate’s linker chemistry and conjugation site are design choices that profoundly alter its stability and release kinetics. A robust bioanalytical package must be designed to precisely measure the consequences of these engineering decisions, providing a clear feedback loop for optimizing the next generation of therapeutics.

Integrated Bioanalytical Strategy

We provide a comprehensive suite of validated assays to support Swissmedic-regulated pharmacokinetic studies for novel antibody-payload conjugates.

Analyte Primary Assay Platform Key Deliverable
Total Antibody Ligand-Binding Assay (ELISA) Total antibody concentration-time profile
Conjugated Antibody Ligand-Binding Assay (ELISA) Active therapeutic concentration-time profile
Unconjugated Payload LC-MS/MS Free payload concentration and metabolite profile
Anti-Drug Antibodies Ligand-Binding Assay (ELISA) Immunogenicity assessment and impact on PK

Our approach provides sponsors with a clear, defensible, and submission-ready dataset that fully characterizes the pharmacokinetic profile of their asset.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities